|CANF -- Israel Stock|| |
ILS 238.90 0.40 0.17%
Can Fite BioPharma Ltd diagnostics interface makes it easy to digest most current publicly released information about Can Fite as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Can Fite price relationship with some important fundamental indicators such as market cap and management efficiency.
Can Fite Note
The company recorded loss per share of 0.17. Can Fite BioPharma Ltd had not issued any dividends in recent years. This company had a split on 2013-05-12. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. Can Fite operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 7 people. For more info on CAN-FITE BIOPHARMA please contact Pnina Fishman at 972 3 924 1114 or go to http://www.canfite.co.il.
Can Fite BioPharma Alerts
|Can Fite BioPharma is not yet fully synchronised with the market data|
|The company reported revenue of 1.55M. Net Loss for the year was (5.84M) with profit before overhead, payroll, taxes, and interest of 789K. |
|CAN-FITE BIOPHARMA has accumulated about 5.84M in cash with (5.38M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. |
The company currently falls under 'Small-Cap' category with current market capitalization of 107.04M.
Can Fite BioPharma Ltd has return on total asset (ROA) of (41.53) %
which means that it has lost $41.53 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (111.36) %
meaning that it generated substantial loss on money invested by shareholders.
Can Fite Technical and Predictive Indicators